TABLE 1.
Serum bactericidal responses after three doses of an investigational meningococcal multicomponent recombinant protein vaccinea
| Strain | 1/GMT (95% CI)b
|
% of subjects with SBA titers of ≥1:4 (95% CI)
|
||
|---|---|---|---|---|
| Pre | Post | Pre | Post | |
| H44/76 | 2.9 (2.2-3.8) A | 64 (38-110) B | 19 (8-36) C | 97 (85-100) D |
| NZ98/254 | 2.5 (2.0-3.0) A | 3.8 (2.4-5.8) B | 11 (3-26) E | 22 (10-39) F |
| S3032 | 2.2 (1.9-2.4) A | 3.8 (2.8-5.3) B | 8 (2-22) G | 36 (21-54) H |
a
The vaccine contained two fusion proteins, GNA 2091-fHbp variant 1 and GNA 2132-GNA 1030, and a third component, recombinant NadA (12). Sera from 36 subjects were tested, except for strain H44/76, for which sera from 35 subjects were tested because of insufficient volume of 1 postimmunization sample.
b
CI, confidence interval; Pre and Post, prevaccination and postvaccination, respectively. For A versus B, P < 0.001 by a paired t test. P values by the Fisher exact test are as follows: <0.001 for C versus D, >0.3 for E versus F, and <0.01 for G versus H.